Azenta and Form Bio Partner to Enhance AAV Gene Therapy

May 13, 2025
Azenta Life Sciences and Form Bio have announced a strategic partnership to advance AAV gene therapy development through integrated sequencing and AI analysis.
Azenta and Form Bio Partner to Enhance AAV Gene Therapy

Azenta Life Sciences and Form Bio have announced a strategic partnership to enhance adeno-associated virus (AAV) gene therapy development. Announced in a press release, the collaboration aims to integrate GENEWIZ's next-generation sequencing services with Form Bio's AI-powered analysis pipelines.

The partnership focuses on providing gene therapy developers with data-driven insights into AAV capsid contents, improving safety, efficacy, and manufacturability. GENEWIZ will offer synthesis and packaging of transgene expression cassettes, along with high-quality, long-read sequencing services. Form Bio will utilize its Long-read AAV Analysis (LAAVA) software for comprehensive AAV Genome Integrity Characterization, offering actionable insights through detailed reporting.

This collaboration is set to officially launch at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in May 2025, where both companies will present their work on integrating sequencing and analysis workflows to accelerate the development of innovative therapies.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.